Fibrocell Science (FCSC) Stock Price, Forecast & Analysis
USA - NASDAQ:FCSC -
FCSC Key Statistics, Chart & Performance
The current stock price of FCSC is 3 null. In the past month the price increased by 0.67%. In the past year, price increased by 50%.
FCSC Latest News, Press Relases and Analysis
About FCSC
Company Profile
Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma.
Company Info
Fibrocell Science
405 EAGLEVIEW BOULEVARD
EXTON PA 19341
CEO: John M. Maslowski
Phone: 484-713-6000
Fibrocell Science / FCSC FAQ
What does FCSC do?
Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma.
What is the current price of FCSC stock?
The current stock price of FCSC is 3 null.
Does Fibrocell Science pay dividends?
FCSC does not pay a dividend.
What is the ChartMill technical and fundamental rating of FCSC stock?
FCSC has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of Fibrocell Science (FCSC)?
The PE ratio for Fibrocell Science (FCSC) is 16.67. This is based on the reported non-GAAP earnings per share of 0.18 and the current share price of 3 null.
What is Fibrocell Science worth?
Fibrocell Science (FCSC) has a market capitalization of 29.27M null. This makes FCSC a Nano Cap stock.
FCSC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to FCSC. When comparing the yearly performance of all stocks, FCSC is one of the better performing stocks in the market, outperforming 82.79% of all stocks.
FCSC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FCSC. FCSC has a medium profitability rating, but doesn't score so well on its financial health evaluation.
FCSC Financial Highlights
Over the last trailing twelve months FCSC reported a non-GAAP Earnings per Share(EPS) of 0.18000000000000005. The EPS increased by 103.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -3.29% | ||
| ROA | -2.7% | ||
| ROE | N/A | ||
| Debt/Equity | 0.47 |